Palvella Therapeutics (NasdaqCM:PVLA) Update / Briefing November 05, 2025 08:30 AM ET Speaker1Stones. Moving left to right, number one, we are charging towards the clinic with our Qtorin Rapamycin for clinically significant angiokeratomas program, our third clinical indication for Qtorin Rapamycin. Number two, today we achieve our second of four milestones with the announcement of our next Qtorin platform program, Qtorin Pitavastatin for the treatment of disseminated superficial actinic porokeratosis. As no ...

Palvella Therapeutics (NasdaqCM:PVLA) Update / Briefing November 05, 2025 08:30 AM ET Speaker2Hello, and thank you for standing by. Welcome to Palvella Therapeutics conference call to discuss new product candidate Qutarwin Bhutab with us. All lines have been placed on mute to prevent any background noise. I would now like to turn the conference over to Bohan Wei. You may begin.Speaker4Thank you, Operator. Good morning, and thank you for joining the Palvella Therapeutics conference call to discuss our new pr ...